Dimerix Limited (AU:DXB)
ASX:DXB
Want to see AU:DXB full AI Analyst Report?
Top Page
Dimerix Limited
(Sydney:DXB)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.20
▼(-50.25% Downside)
Action:ReiteratedDate:04/30/26
The score is held down primarily by weak financial quality (persistent negative margins, very negative ROE, and steeply declining free cash flow growth) and bearish technicals (price below all major moving averages with negative MACD). Valuation provides only limited offset because the negative P/E reflects losses and no dividend yield is available.
Positive Factors
Revenue Growth
Consistent high revenue growth (70.03%) indicates expanding commercial traction or milestone-driven topline expansion; over several months this supports sustained R&D funding, validates demand for lead programs like DMX-200, and can improve unit economics as fixed costs are spread with scale.
Negative Factors
Profitability
Persistently negative net and EBIT margins (-10.56% and -28.97%) reflect structural unprofitability driven by high operating and development costs. Over a multi-month horizon, sustained losses increase financing needs and suggest the company must materially improve margins or secure recurring revenue to achieve long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent high revenue growth (70.03%) indicates expanding commercial traction or milestone-driven topline expansion; over several months this supports sustained R&D funding, validates demand for lead programs like DMX-200, and can improve unit economics as fixed costs are spread with scale.
Read all positive factors
Dimerix Limited (DXB) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$129.09M
Dividend YieldN/A
Average Volume (3M)1.47M
Price to Earnings (P/E)―
Beta (1Y)2.45
Revenue Growth1219.92%
EPS Growth38.88%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding600,396,800
10 Day Avg. Volume1,720,426
30 Day Avg. Volume1,468,144
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)24.09
Price to Sales (P/S)256.86
P/FCF Ratio8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$18.30M
Dimerix Limited Business Overview & Revenue Model
Company Description
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical ...
How the Company Makes Money
null...
Dimerix Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
40
Negative
Cash Flow
50
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.42M | 1.25M | 583.48K | 36.79K | 6.46M | 4.44M |
| Gross Profit | 5.30M | 1.25M | 583.48K | 36.79K | 6.41M | 4.39M |
| EBITDA | -40.31M | -36.22M | -24.96M | -22.68M | -16.47M | -10.02M |
| Net Income | -16.31M | -13.25M | -17.07M | -13.80M | -10.49M | -6.37M |
Balance Sheet | ||||||
| Total Assets | 64.56M | 91.18M | 32.08M | 17.76M | 16.50M | 9.42M |
| Cash, Cash Equivalents and Short-Term Investments | 38.49M | 68.28M | 22.14M | 7.99M | 9.63M | 5.25M |
| Total Debt | 33.42K | 97.48K | 149.68K | 5.96M | 73.10K | 5.09M |
| Total Liabilities | 66.24M | 77.80M | 13.89M | 11.79M | 2.07M | 7.95M |
| Stockholders Equity | -1.68M | 13.38M | 18.19M | 5.96M | 14.42M | 1.47M |
Cash Flow | ||||||
| Free Cash Flow | 11.43M | 39.03M | -7.02M | -12.73M | -13.45M | -6.47M |
| Operating Cash Flow | 11.44M | 39.05M | -7.00M | -12.73M | -13.44M | -6.46M |
| Investing Cash Flow | -10.56K | -21.01K | -15.80K | -2.30K | -10.61K | 4.38K |
| Financing Cash Flow | 6.38M | 7.42M | 21.17M | 11.07M | 17.69M | 3.83M |
Dimerix Limited Technical Analysis
Neutral
0.40
Price Trends
0.40
Negative
0.47
Negative
0.49
Negative
Market Momentum
<0.01
Negative
58.91
Neutral
87.30
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:DXB, the sentiment is Neutral. The current price of 0.4 is above the 20-day moving average (MA) of 0.34, below the 50-day MA of 0.40, and below the 200-day MA of 0.49, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.91 is Neutral, neither overbought nor oversold. The STOCH value of 87.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:DXB.
Dimerix Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$477.55M | 14.96 | 13.29% | 0.38% | 5.17% | -16.14% | |
54 Neutral | AU$510.78M | -29.29 | -47.44% | ― | ― | -15.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$129.09M | -5.17 | -278.87% | ― | 1219.92% | 38.88% | |
44 Neutral | AU$91.87M | -14.80 | -40.65% | ― | -100.00% | -11.11% | |
42 Neutral | AU$88.42M | -3.40 | -69.20% | ― | ― | -73.11% | |
41 Neutral | AU$233.71M | -12.98 | -44.80% | ― | 49.03% | -232.68% |
* Healthcare Sector Average
AU:DXB
Dimerix Limited
0.22
-0.40
-64.75%
AU:CUV
Clinuvel Pharmaceuticals
9.47
-1.46
-13.33%
AU:OCC
Orthocell Ltd
0.86
-0.48
-35.82%
AU:IMM
Immutep Ltd
0.06
-0.23
-79.31%
AU:RAC
Race Oncology Ltd.
2.73
1.40
105.26%
AU:ALA
Arovella Therapeutics Limited
0.08
>-0.01
-9.52%
Dimerix Limited Corporate Events
Dimerix Highlights ACTION3 Trial De-Risking and Commercial Potential for DMX-200
Apr 28, 2026
Dimerix Limited has released an updated investor presentation and video detailing progress on its Phase 3 ACTION3 trial of lead kidney disease candidate DMX-200, following blinded statistical analysis results. The materials outline the companyR...
Dimerix Confirms Strong Statistical Power and Refines Strategy for Phase 3 FSGS Trial
Apr 27, 2026
Dimerix has confirmed that its Phase 3 ACTION3 trial of DMX-200 in FSGS remains statistically well powered, with a blinded external review showing more than a 90% chance of demonstrating a significant treatment effect on the primary endpoint of pr...
Dimerix to Court Singapore Investors With Update on Phase 3 Kidney Drug
Apr 9, 2026
Dimerix Limited has announced an updated venue and details for an investor lunch briefing in Singapore on 20 April 2026, where CEO and Managing Director Dr Nina Webster will outline progress of the global ACTION3 Phase 3 trial in FSGS kidney disea...
Dimerix Over-Recruits in Pivotal FSGS Phase 3 Trial as Last Adult Patient Dosed
Mar 9, 2026
Dimerix has completed enrolment and first dosing of the last adult patient in its pivotal ACTION3 Phase 3 trial of DMX-200 for focal segmental glomerulosclerosis, bringing adult recruitment to 333 patients and closing further adult recruitment. Th...
Dimerix Courts Investors With Perth and Singapore Briefings on FSGS Phase 3 Program
Mar 3, 2026
Dimerix Limited has invited existing and potential investors to attend interactive briefings in Perth on 16 March 2026 and in Singapore on 20 April 2026, where executives will provide updates on the global ACTION3 Phase 3 trial of DMX-200 in FSGS ...
Dimerix to Showcase Phase 3 FSGS Program at Oppenheimer Healthcare Conference
Feb 27, 2026
Dimerix Limited will present an update on its Phase 3 ACTION3 trial of DMX-200 for FSGS kidney disease at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference in New York and virtually on 27 February 2026. CEO Dr Nina Webster will o...
Dimerix Revenue Surges but Loss Deepens and Asset Base Thins
Feb 26, 2026
Biotechnology developer Dimerix Limited reported a sharp increase in revenue from ordinary activities for the half-year to 31 December 2025, with income rising 388% to $2.32 million. However, the company remains deeply loss-making, underscoring th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.